- Fee assured
- Verified this account
Dr Rebecca Kristeleit is Clinical Senior Lecturer and Consultant Medical Oncologist at UCL/UCLH. She specialises in the treatment of gynaecological cancers:
She also has a specialist interest in drug development as well and is leading several clinical trials of novel agents relevant to gynecological malignancies including PARP inhibitors.
Rebecca qualified in medicine from St Andrew’s and Manchester Universities including eight months at the University of Lausanne (Switzerland) on an Erasmus scholarship. Following general medical training in London, Rebecca undertook her medical oncology training at The Royal Marsden Hospital and a CRUK-funded research fellowship at the Institute of Cancer Research. Subsequently, Rebecca spent a year as a senior research fellow on the Drug Development Unit at the Royal Marsden Hospital gaining specialist experience in the design and conduct of early phase clinical trials and translational medicine.
Areas of interest
Cervical Cancer; Endometrial Cancer ; Ovarian Cancer; Clinical Trials
Current NHS consultant posts held
Clinical Senior Lecturer and Consultant Medical Oncologist at UCL/UCLH.
Dr Kristeleit's research work, as part of the UCLH gynecological oncology team, Clinical Research Facility at UCLH and the UCL Cancer Institute, is focused on the development of early phase clinical trials and translational research to identify and evaluate innovative treatment strategies for gynecological malignancies as well as other solid tumours.
Reference number 4178152
- London Clinic
- 09:00 - 13:00
- 020 3219 3599
Post treatment communication
Following treatment of a Bupa member, I will communicate with GPs in line with Department of Health, GMC and appropriate professional bodies guidelines.
In the event of an urgent query following treatment, Bupa members should use the following contact details
9am-5pm Monday - Friday please call the secretary on 0203 219 3599. Out of office hours please call the hospital where you are being treated.
Information for healthcare professionals (Bupa patients only, last 12 months)
Clinical supervision and planning for delivery of chemotherapy cycle 1 - 21 days - (5-50)
Clinical supervision and planning for delivery of chemotherapy cycle 1 - 28 days - (5-50)
Therapeutic oesophago-gastro-duodenoscopy (OGD) with insertion of prosthesis - (5-50)
Insertion of implantable central venous port (portacath) e.g Port-a-Cath under image guidance - (1-5)
Clinical supervision and planning for delivery of chemotherapy cycle 1 - 14 days - (1-5)
- Show All (8)...